• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

塑造靶向蛋白质降解途径的细胞参数。

Cellular parameters shaping pathways of targeted protein degradation.

作者信息

Cardno Annabel, Kennedy Bryony, Lindon Catherine

机构信息

Department of Pharmacology, University of Cambridge, Cambridge, UK.

出版信息

Commun Biol. 2025 May 2;8(1):691. doi: 10.1038/s42003-025-08104-w.

DOI:10.1038/s42003-025-08104-w
PMID:40316744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12048530/
Abstract

In recent years the development of proteolysis-targeting chimeras (PROTACs) has enhanced the field of ubiquitin signalling through advancing therapeutic targeted protein degradation (TPD) strategies and generating tools to explore the ubiquitin landscape. However, the interplay between PROTACs and their substrates, and other components of the ubiquitin proteasome system (UPS), raises fundamental questions about cellular parameters that might influence the action of PROTACs and the amenability of a given target to PROTAC-mediated degradation. In this perspective we discuss examples of cellular parameters that have been shown to influence PROTAC sensitivity and consider others likely to be important for PROTAC-mediated target degradation but not yet routinely considered in design of novel TPD strategies: Target localisation and accessibility on the one hand, and expression patterns, localisation and activity of E3 ligases, deubiquitinases (DUBs) and wider ubiquitin machinery on the other, are critical parameters in the exploitation of PROTACs, and establishing a better understanding of these parameters will facilitate the rational design of PROTACs.

摘要

近年来,靶向蛋白降解嵌合体(PROTACs)的发展通过推进治疗性靶向蛋白降解(TPD)策略以及生成探索泛素格局的工具,增强了泛素信号传导领域。然而,PROTACs与其底物以及泛素蛋白酶体系统(UPS)的其他组分之间的相互作用,引发了关于可能影响PROTACs作用以及给定靶点对PROTAC介导降解的适应性的细胞参数的基本问题。从这个角度出发,我们讨论了已被证明会影响PROTAC敏感性的细胞参数示例,并考虑了其他可能对PROTAC介导的靶点降解很重要但在新型TPD策略设计中尚未常规考虑的参数:一方面是靶点的定位和可及性,另一方面是E3连接酶、去泛素化酶(DUBs)和更广泛的泛素机制的表达模式、定位和活性,这些都是利用PROTACs的关键参数,更好地理解这些参数将有助于PROTACs的合理设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/a3764cd830c0/42003_2025_8104_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/7322d1eb3bf4/42003_2025_8104_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/dc2592165e80/42003_2025_8104_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/a3764cd830c0/42003_2025_8104_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/7322d1eb3bf4/42003_2025_8104_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/dc2592165e80/42003_2025_8104_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f1f/12048530/a3764cd830c0/42003_2025_8104_Fig3_HTML.jpg

相似文献

1
Cellular parameters shaping pathways of targeted protein degradation.塑造靶向蛋白质降解途径的细胞参数。
Commun Biol. 2025 May 2;8(1):691. doi: 10.1038/s42003-025-08104-w.
2
Proteasome substrate receptors and their therapeutic potential.蛋白酶体底物受体及其治疗潜力。
Trends Biochem Sci. 2022 Nov;47(11):950-964. doi: 10.1016/j.tibs.2022.06.006. Epub 2022 Jul 9.
3
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.泛素化和去泛素化在癌症中的作用:从机制到新的治疗方法。
Mol Cancer. 2024 Jul 25;23(1):148. doi: 10.1186/s12943-024-02046-3.
4
Proteolysis-targeting chimeras (PROTACs) in cancer therapy.蛋白水解靶向嵌合体(PROTACs)在癌症治疗中的应用。
Mol Cancer. 2022 Apr 11;21(1):99. doi: 10.1186/s12943-021-01434-3.
5
Applications of protein ubiquitylation and deubiquitylation in drug discovery.蛋白质泛素化和去泛素化在药物发现中的应用。
J Biol Chem. 2024 May;300(5):107264. doi: 10.1016/j.jbc.2024.107264. Epub 2024 Apr 4.
6
Fragment-based approaches to discover ligands for tumor-specific E3 ligases.基于片段的方法发现肿瘤特异性E3连接酶的配体。
Expert Opin Drug Discov. 2024 Dec;19(12):1471-1484. doi: 10.1080/17460441.2024.2415310. Epub 2024 Oct 17.
7
PROTAC-DB 2.0: an updated database of PROTACs.PROTAC-DB 2.0:一个更新的 PROTAC 数据库。
Nucleic Acids Res. 2023 Jan 6;51(D1):D1367-D1372. doi: 10.1093/nar/gkac946.
8
PROTACs: past, present and future.PROTACs:过去、现在和未来。
Chem Soc Rev. 2022 Jun 20;51(12):5214-5236. doi: 10.1039/d2cs00193d.
9
[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].[PROTACs及其他策略诱导的蛋白质降解:迈向有前景的药物]
Biol Aujourdhui. 2021;215(1-2):25-43. doi: 10.1051/jbio/2021007. Epub 2021 Aug 16.
10
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.蛋白水解靶向嵌合体(PROTACs)是血液系统恶性肿瘤的新兴治疗药物。
J Hematol Oncol. 2020 Jul 27;13(1):103. doi: 10.1186/s13045-020-00924-z.

本文引用的文献

1
Workflow for E3 Ligase Ligand Validation for PROTAC Development.用于PROTAC开发的E3连接酶配体验证工作流程。
ACS Chem Biol. 2025 Feb 21;20(2):507-521. doi: 10.1021/acschembio.4c00812. Epub 2025 Feb 11.
2
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera.利用双连接酶招募通过异三价靶向嵌合体增强蛋白质降解。
J Am Chem Soc. 2024 Dec 11;146(49):33675-33711. doi: 10.1021/jacs.4c11556. Epub 2024 Nov 28.
3
Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.
DCAF1-PROTAC-WDR5 三元复合物的晶体结构为 DCAF1 底物特异性提供了深入了解。
Nat Commun. 2024 Nov 23;15(1):10165. doi: 10.1038/s41467-024-54500-x.
4
Intrinsic signaling pathways modulate targeted protein degradation.内在信号通路调节靶向蛋白降解。
Nat Commun. 2024 Jul 2;15(1):5379. doi: 10.1038/s41467-024-49519-z.
5
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.在活细胞中追踪 PROTAC 降解途径强调了测量三元复合物对于 PROTAC 优化的重要性。
Cell Chem Biol. 2023 Jul 20;30(7):753-765.e8. doi: 10.1016/j.chembiol.2023.06.002. Epub 2023 Jun 23.
6
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.通过 PROTAC 753B 双重靶向 BCL-XL 和 BCL-2 可消除白血病细胞,并通过靶向衰老细胞增强化疗效果。
Haematologica. 2023 Oct 1;108(10):2626-2638. doi: 10.3324/haematol.2022.281915.
7
c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer.基于 TNA-DNA 双价结合物的 c-Myc 靶向 PROTAC 用于三阴性乳腺癌的联合治疗。
J Am Chem Soc. 2023 Apr 26;145(16):9334-9342. doi: 10.1021/jacs.3c02619. Epub 2023 Apr 17.
8
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?招募 Cereblon 的 PROTAC:新药是否必须面对旧挑战?
Pharmaceutics. 2023 Mar 2;15(3):812. doi: 10.3390/pharmaceutics15030812.
9
PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components.靶向蛋白降解嵌合体连接体化学优化导致多梳抑制复合物 2(PRC2)组件的双价化学降解剂。
ACS Chem Biol. 2023 Mar 17;18(3):494-507. doi: 10.1021/acschembio.2c00804. Epub 2023 Mar 6.
10
Targeting androgen receptor degradation with PROTACs from bench to bedside.利用 PROTAC 靶向雄激素受体降解:从实验室到临床。
Biomed Pharmacother. 2023 Feb;158:114112. doi: 10.1016/j.biopha.2022.114112. Epub 2022 Dec 9.